Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years Curium partners with Institut Laue–Langevin to enhance Lutetium-177 supply, benefiting over 100,000 cancer patients in five years.